Ozempic Sat Unused for Decades Because Invention Is Not Enough
Why Read This
What Makes This Article Worth Your Time
Summary
What This Article Is About
Per Bylund examines why semaglutide—now sold as Ozempic and Wegovy—sat dormant for roughly 30 years after a startup first developed the GLP-1 compound and Pfizer confirmed its efficacy through human trials. Despite promising early results, Pfizer abandoned the project in 1991, convinced no injectable diabetes therapy beyond insulin would ever succeed, and the startup folded.
Bylund argues this is a story of entrepreneurial failure, not just bad luck: inventions alone create little value without the entrepreneurial judgment to recognize and execute their market potential. He compares Pfizer’s missed opportunity to historical cases like Tesla, Elias Howe, and Henry Ford, illustrating the concept of second-mover advantage and why execution often matters more than invention itself.
Key Points
Main Takeaways
A 30-Year Delay
The GLP-1 compound behind Ozempic was developed and proven effective in the late 1980s, yet sat largely untouched for roughly three decades.
Pfizer Abandoned a Winning Drug
Despite confirmed efficacy in human trials, Pfizer pulled funding in 1991 after concluding no other injectable diabetes therapy would ever succeed.
Invention Alone Has Little Value
Bylund argues that ideas and discoveries only become valuable once entrepreneurs execute and operationalize them into usable products.
History Repeats: Tesla, Howe, Meucci
Like the GLP-1 story, inventors such as Nikola Tesla and Elias Howe failed to capture the full value of their own breakthroughs.
Second-Mover Advantage Explained
Novo Nordisk succeeded by recognizing and developing the market potential Pfizer missed, illustrating how later entrants often outperform first movers.
Pfizer Missed the Real Market
Pfizer viewed GLP-1 solely as a diabetes treatment, completely missing the massive non-diabetic weight-loss market driving today’s Ozempic demand.
Master Reading Comprehension
Practice with 365 curated articles and 2,400+ questions across 9 RC types.
Article Analysis
Breaking Down the Elements
Main Idea
Execution, Not Invention, Creates Value
Bylund’s central argument is that the GLP-1 compound’s three-decade dormancy demonstrates a broader economic truth: inventions and discoveries hold little inherent value until entrepreneurs recognize their market potential and execute the difficult work of operationalizing them into products people are willing to pay for.
Purpose
Illustrating an Economic Principle Through History
Bylund writes to persuade readers that entrepreneurial judgment, not invention itself, drives economic value, using Ozempic alongside historical cases like Tesla and Henry Ford to argue against the popular narrative of mistreated geniuses, while teaching the underappreciated concept of second-mover advantage.
Structure
Narrative → Historical Comparison → Economic Lesson
The piece opens with the specific story of Ozempic’s stalled development, broadens into a survey of similar historical cases of inventors losing out to entrepreneurs, then concludes by extracting the general economic lesson of second-mover advantage and the primacy of execution over invention.
Tone
Analytical, Instructive & Slightly Critical
Bylund’s tone is measured and explanatory, using Pfizer’s misjudgment as a teaching example rather than an outright condemnation, blending economic analysis with engaging historical anecdotes to make an academic argument about entrepreneurship accessible and persuasive to general business readers unfamiliar with economic theory.
Key Terms
Vocabulary from the Article
Click each card to reveal the definition
Build your vocabulary systematically
Each article in our course includes 8-12 vocabulary words with contextual usage.
Tough Words
Challenging Vocabulary
Tap each card to flip and see the definition
Greatly astonished or shocked into silence or confusion.
“I was equally dumbfounded by their decision to end their investment”
Troubled or afflicted persistently and severely by something harmful.
“In a world plagued by increasing obesity”
Not used, handled, or affected in any way; left in its original state.
“why did the formula sit untouched for 30 years”
Payments made to the owner of a patent or creative work for the right to use it.
“compelled to pay the inventor royalties”
A popular but often misleading narrative crediting one brilliant individual for success.
“Tesla, the lone genius, struggled with poverty”
Benefiting from a resource or idea without contributing proportionally to its creation.
“free-riding on a mistreated genius”
Reading Comprehension
Test Your Understanding
5 questions covering different RC question types
1According to the article, Pfizer pulled funding from the GLP-1 project in 1991 after concluding that no injectable diabetes therapy other than insulin would ever succeed.
2According to the article, who eventually acquired the GLP-1 license and developed it into semaglutide?
3Which sentence best captures Bylund’s central thesis about invention versus entrepreneurship?
4Evaluate the following statements about the historical examples Bylund uses to support his argument:
George Westinghouse bought patents from Nikola Tesla and commercialized his ideas.
Elias Howe successfully retained all profits from his sewing machine invention.
Henry Ford invented the automobile but failed to make it affordable.
Select True or False for all three statements, then click “Check Answers”
5Based on the article’s argument, what can be inferred about why Pfizer’s mistake with GLP-1 occurred?
FAQ
Frequently Asked Questions
Senior Pfizer leadership concluded there would never be another viable injectable diabetes therapy besides insulin, despite convincing early evidence of the drug’s success in human trials, leading the company to pull its funding and causing the startup developing the compound to fold.
Second-mover advantage describes how a later market entrant, like Novo Nordisk with Ozempic, can succeed where the first innovator failed—not merely by avoiding the first mover’s costly mistakes, but by recognizing a new idea’s true market potential and executing it more effectively.
These examples reinforce Bylund’s argument that the gap between invention and successful commercialization is a recurring pattern in business history, showing that even brilliant inventors often fail to capture their idea’s full value without the entrepreneurial execution that figures like Westinghouse and Ford provided.
Readlite provides curated articles with comprehensive analysis including summaries, key points, vocabulary building, and practice questions across 9 different RC question types. Our Ultimate Reading Course offers 365 articles with 2,400+ questions to systematically improve your reading comprehension skills.
This article is rated Intermediate because it introduces economic and business concepts like entrepreneurial judgment, value proposition, and second-mover advantage through accessible historical storytelling, requiring some familiarity with basic business terminology but no advanced economic theory background, making it suitable for general readers interested in entrepreneurship.
Per Bylund is an economist whose writing for The Daily Economy often applies Austrian-school economic thinking to business history, and in this piece he uses the Ozempic case to argue that entrepreneurial judgment and execution, not mere invention, are what create genuine economic value.
The Ultimate Reading Course covers 9 RC question types: Multiple Choice, True/False, Multi-Statement T/F, Text Highlight, Fill in the Blanks, Matching, Sequencing, Error Spotting, and Short Answer. This comprehensive coverage prepares you for any reading comprehension format you might encounter.
